Table 2.

Abbreviated geriatric assessment tools

Abbreviations: ADL, activities of daily living; MNA-SF, mini-nutritional assessment short form; BP, blood pressure, IADL, instrumental activities of daily living; LDH, lactate dehydrogenase; MMSE, mini mental state examination; MNA, mini nutritional assessment; BMI, body mass index; HADS, hospital anxiety and depression scale

Study	Inclusion Criteria	Regimens assessed	n	Survival (PFS and OS)	Key points
GINECO [78]	>70 years Stage III/IV	Carboplatin/Cyclophospha mide	83	OS 21.6 months	Post-hoc analysis. 75% patients completed planned 6 cycles ECOG PS not predictive for survival
GINECO – Analysis of two consecutive trials [79]	>70 years Stage III/IV	Carboplatin/Paclitaxel	75	OS 25.9 months	Prospective study. 68% patients completed planned 6 cycles. Depressive symptoms at baseline predictive for OS
AGO-OVAR [40]	>70 years	Carboplatin/Paclitaxel vs. Cisplatin/Paclitaxel	103	Not reported	Post-hoc analysis. High proportion of PS 0/1 No difference in quality of life Older patients more likely to discontinue treatment early despite comparable reported toxicity rates
MITO-5 [43]	>70 Stage IC-IV	Dose-dense weekly Carboplatin/weekly Paclitaxel	27	OS 32 months	Prospective study. 65% patients completed planned six cycles Favorable toxicity profile
GINECO/GVS [80]	>70 years Stage III/IV	Carboplatin Monotherapy (AUC 5)	109	PFS 9.2 months OS 17.4 months	Prospective study. 74% patients completed planned 6 cycles. Results have informed design of prospective study utilising GVS score
GOG0273 [81]	>70 years	I: Carboplatin AUC5 and Paclitaxel 135mg/m2 or II: Carboplatin AUC 5 3 weekly for 4 cycles	208	Not yet reported	Prospective study. Physicians choice of regimen I or II IADL not associated with ability to complete chemotherapy without delay or dose reduction Limitation of social activities associated with decreased tolerance to chemotherapy 3rd arm of weekly Paclitaxel added; results awaited.